IRVINE, Calif., Jan. 14, 2008 (PRIME NEWSWIRE) -- "It seems ironic that a publication that is near-ubiquitous in doctor's offices everywhere will be featuring an angiogenesis therapy that hopes to become a potent tool in modern heart medicine. It's even more flattering that the February Reader's Digest article boldly refers to CardioVascular BioTherapeutics, Inc's (OTCBB:CVBT) angiogenesis therapy as 'a new lease on life," stated SmallCap Sentinel analyst D.R. Clark. "The article titled, 'Heart Hope' refers to CVBT's therapy for patients suffering from severe coronary heart disease who do not have any other viable treatment options. Patients such as those featured in the Reader's Digest article could benefit from this innovative treatment where conventional methods have failed them. Angiogenesis refers to the growth of new blood vessels that may help those suffering from coronary heart disease by increasing blood flow to the affected tissue."
An informational report featuring Cardiovascular BioTherapeutics is available at: http://stockupticks.com/profiles/2-2-06.html and contains data and information of interest to cardiac-related companies including CVBT, Boston Scientific Corporation (NYSE:BSX), Medtronic, Inc., (NYSE:MDT), and Cardium Therapeutics, Inc. (AMEX:CXM).
"CVBT's inclusion in Reader's Digest, which is still the best-selling consumer magazine in the United States with a circulation of over 10 million domestic copies and a readership of 38 million, is assuredly a landmark moment for this intriguing equity," Clark noted.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase Ib or Phase II trial to treat dermal wound healing in diabetics (CVBT-141B) is planned to begin in 2008.
For ongoing information regarding the aforementioned public companies please register at http://stockupticks.com/register.html
To be featured in SmallCap Sentinel contact us at the number below.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP isn't an investment advisor and this report isn't investment advice. MP has been granted 20,000 restricted shares by CVBT for preparation and distribution of this report and other advertising. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664